About inno.N
Since its establishment in 1984, with a team of experienced experts, inno.N has achieved many successes in the pharmaceutical industry and gained the trust of the people, becoming the leading pharmaceutical company in Korea.
inno.N Spirit
Aspiration for Innovation
inno.N’s commitment to innovation is well captured in the company’s name. We remain committed to taking on new perspectives, bringing together the possibilities of biopharmaceuticals to open the next chapter towards a better future.
Excellence in Customer Service
We see customers as not ‘the other party’ but people who represent our ultimate goal. inno.N will continue to serve its existing customers with some of the best products and services, while also reaching out to new and potential customers, lending an ear to what the customer has to say in the process.
Mutual Respect
We avoid the trap of thinking to be different is to be wrong. We recognize the diversity in thoughts and ideas, promote open communication and collaboration based on mutual respect.
Trustworthiness and Integrity
We do not compromise for short-term profits. Even if it means a detour, we prioritize ethical management and social responsibility.
Collective Growth
We do not compromise for short-term profits. Even if it means a detour, we prioritize ethical management and social responsibility.
A LETTER FROM OUR CEO
Dalwon Kwak
To achieve our mission, ‘Heal the World for Better Life’, we initiated Innovation No.1 inno.N with the goal to develop ground-breaking drugs for the world’s health and in the spirit of creation, innovation, and gratitude towards customers who support us.
inno.N’s R&D
With a global Standard IT system and priority placed on the data integrity, inno.N operates a quality management system in accordance with the standards of cGMP/EU GMP.
Osong Plant
In 2006, we successfully strengthened our product portfolio by merge and acquisition of Han-il Pharmaceutical Corp. In 2010, we completed the construction of the Osong plant, the world-class pharmaceutical production facility, giving a leap to become a global pharmaceutical company.
EPOKINE
In 1995, inno.N was the first domestic pharmaceutical company to achieve $ 100 million in exports and led the growth of the industry. With the continuous R&D investment, we launched a renal anemia treatment EPO formulation (product name: EPOKINE) in 1998 and this was the world's third and for the first time in Korea, leading the localization of pharmaceuticals.
CONDITION
CONDITION, the most popular anti-hangover drink in Korea, has been the indisputable No. 1 brand since 1992 when it first opened the anti-hangover drink market in Korea.
Bag-type IV Solutions
By producing safe-flex bags for the first time in Korea in 1992, we have brought innovation to the healthcare environment where glass containers used to cause inconvenience in use.
HEPACCINE-B
In 1986, we developed hepatitis prevention vaccine 'Hepaccin-B' with pure domestic technology. We were recognized for our technological capability by mass-producing ‘interferon,’ which was a state-of-the-art basic medicine at that time and 7-ACA, the raw material that requires fine chemical technology.
Into the future
In an effort to build a stronger foundation for a 100-year company that started with CJ Healthcare and advanced into inno.N, we are working to create a more substantial impact on the global high-tech pharmaceutical industry in 2020.
In March 2019, inno.N launched K-CAB Tab.(Ingredient name: tegoprazan), a new drug for Gastroesophageal acid reflux disease in Korea. K-CAB Tab not only yields the most effective among newly developed drugs within the first year of its launch, but it was also exported to 22 other countries: China, Thailand, Indonesia, and 17 nations in Central and South America.
By means of Open Innovation with technologies from both domestic and overseas branches, inno.N accelerates the speed and effectiveness of newly developed drugs while investing in new technologies for the future.
In 2014, inno.N partnered with Pangen to co-develop protein therapeutics. In May 2016, we signed a joint development contract with Y-BioLogics, a new antibody developing company with the purpose of researching dual-target antibodies, anti-cancer immune drugs. Moreover, inno.N is also leading in the country’s pharmaceutical industry owing to our adaptation of innovative technologies advanced technologies from venture companies in the US, Japan, and Europe.